Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

Background and Aim: Data on the clinical pharmacokinetics of cannabidiol (CBD) are scanty. We explored the effect of demographic and clinical variables on plasma concentrations of purified CBD in patients with Dravet (DS) and Lennox–Gastaut syndrome (LGS). Methods: The study design was an open, pros...

Descripción completa

Detalles Bibliográficos
Autores principales: Contin, Manuela, Mohamed, Susan, Santucci, Margherita, Lodi, Monica Anna Maria, Russo, Emilio, Mecarelli, Oriano, CBD LICE Italy Study Group
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966506/
https://www.ncbi.nlm.nih.gov/pubmed/33746760
http://dx.doi.org/10.3389/fphar.2021.637801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966506/
https://www.ncbi.nlm.nih.gov/pubmed/33746760
http://dx.doi.org/10.3389/fphar.2021.637801

Ejemplares similares